Cathepsin B abundance, activity and microglial localisation in Alzheimer's disease-Down syndrome and early onset Alzheimer's disease; the role of elevated cystatin B

被引:2
|
作者
Wu, Yixing [1 ]
Mumford, Paige [1 ]
Noy, Suzanna [2 ]
Cleverley, Karen [2 ]
Mrzyglod, Alicja [1 ]
Luo, Dinghao [1 ]
van Dalen, Floris [3 ,4 ]
Verdoes, Martijn [3 ,4 ]
Fisher, Elizabeth M. C. [2 ]
Wiseman, Frances K. [1 ]
机构
[1] UCL, UK Dementia Res Inst, Queen Sq, London WC1N 3BG, England
[2] UCL, Queen Sq Inst Neurol, Dept Neuromuscular Dis, Queen Sq, London WC1N 3BG, England
[3] Radboudumc, Dept Med Biosci, Geert Grooteplein Zuid 28, NL-6525 GA Nijmegen, Netherlands
[4] Inst Chem Immunol, Geert Grooteplein Zuid 28, NL-6525 GA Nijmegen, Netherlands
基金
英国医学研究理事会; 英国惠康基金;
关键词
Down syndrome; Alzheimer's disease; Cathepsin B; Cystatin B; MOUSE MODEL; UP-REGULATION; BRAIN; INDIVIDUALS; DYSFUNCTION; MEMORY;
D O I
10.1186/s40478-023-01632-8
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Cathepsin B is a cysteine protease that is implicated in multiple aspects of Alzheimer's disease pathogenesis. The endogenous inhibitor of this enzyme, cystatin B (CSTB) is encoded on chromosome 21. Thus, individuals who have Down syndrome, a genetic condition caused by having an additional copy of chromosome 21, have an extra copy of an endogenous inhibitor of the enzyme. Individuals who have Down syndrome are also at significantly increased risk of developing early-onset Alzheimer's disease (EOAD). The impact of the additional copy of CSTB on Alzheimer's disease development in people who have Down syndrome is not well understood. Here we compared the biology of cathepsin B and CSTB in individuals who had Down syndrome and Alzheimer's disease, with disomic individuals who had Alzheimer's disease or were ageing healthily. We find that the activity of cathepsin B enzyme is decreased in the brain of people who had Down syndrome and Alzheimer's disease compared with disomic individuals who had Alzheimer's disease. This change occurs independently of an alteration in the abundance of the mature enzyme or the number of cathepsin B+ cells. We find that the abundance of CSTB is significantly increased in the brains of individuals who have Down syndrome and Alzheimer's disease compared to disomic individuals both with and without Alzheimer's disease. In mouse and human cellular preclinical models of Down syndrome, three-copies of CSTB increases CSTB protein abundance but this is not sufficient to modulate cathepsin B activity. EOAD and Alzheimer's disease-Down syndrome share many overlapping mechanisms but differences in disease occur in individuals who have trisomy 21. Understanding this biology will ensure that people who have Down syndrome access the most appropriate Alzheimer's disease therapeutics and moreover will provide unique insight into disease pathogenesis more broadly.
引用
收藏
页数:19
相关论文
共 50 条
  • [1] Cathepsin B abundance, activity and microglial localisation in Alzheimer’s disease-Down syndrome and early onset Alzheimer’s disease; the role of elevated cystatin B
    Yixing Wu
    Paige Mumford
    Suzanna Noy
    Karen Cleverley
    Alicja Mrzyglod
    Dinghao Luo
    Floris van Dalen
    Martijn Verdoes
    Elizabeth M. C. Fisher
    Frances K. Wiseman
    Acta Neuropathologica Communications, 11
  • [2] The amyloid plaque proteome in early onset Alzheimer's disease and Down syndrome
    Drummond, Eleanor
    Kavanagh, Tomas
    Pires, Geoffrey
    Marta-Ariza, Mitchell
    Kanshin, Evgeny
    Nayak, Shruti
    Faustin, Arline
    Berdah, Valentin
    Ueberheide, Beatrix
    Wisniewski, Thomas
    ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2022, 10 (01)
  • [3] Astroglial and microglial pathology in Down syndrome: Focus on Alzheimer's disease
    Garcia, Octavio
    Flores-Aguilar, Lisi
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2022, 16
  • [4] Comparison of the amyloid plaque proteome in Down syndrome, early-onset Alzheimer's disease, and late-onset Alzheimer's disease
    Marta-Ariza, Mitchell
    Leitner, Dominique F.
    Kanshin, Evgeny
    Suazo, Jianina
    Giusti Pedrosa, Ana
    Thierry, Manon
    Lee, Edward B.
    Devinsky, Orrin
    Drummond, Eleanor
    Fortea, Juan
    Lleo, Alberto
    Ueberheide, Beatrix
    Wisniewski, Thomas
    ACTA NEUROPATHOLOGICA, 2025, 149 (01)
  • [5] Microglial Cathepsin B and Porphyromonas gingivalis Gingipains as Potential Therapeutic Targets for Sporadic Alzheimer's Disease
    Nakanishi, Hiroshi
    Nonaka, Saori
    Wu, Zhou
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2020, 19 (07) : 495 - 502
  • [6] The amyloid plaque proteome in early onset Alzheimer’s disease and Down syndrome
    Eleanor Drummond
    Tomas Kavanagh
    Geoffrey Pires
    Mitchell Marta-Ariza
    Evgeny Kanshin
    Shruti Nayak
    Arline Faustin
    Valentin Berdah
    Beatrix Ueberheide
    Thomas Wisniewski
    Acta Neuropathologica Communications, 10
  • [7] The Role of Microglial Cell Subsets in Alzheimer's Disease
    Naert, G.
    Rivest, S.
    CURRENT ALZHEIMER RESEARCH, 2011, 8 (02) : 151 - 155
  • [8] Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease
    Johannesson, Malin
    Sahlin, Charlotte
    Soderberg, Linda
    Basun, Hans
    Falting, Johanna
    Moller, Christer
    Zachrisson, Olof
    Sunnemark, Dan
    Svensson, Anne
    Odergren, Tomas
    Lannfelt, Lars
    MOLECULAR AND CELLULAR NEUROSCIENCE, 2021, 114
  • [9] Exosomal biomarkers in Down syndrome and Alzheimer's disease
    Hamlett, Eric D.
    Ledreux, Aurelie
    Potter, Huntington
    Chial, Heidi J.
    Patterson, David
    Espinosa, Joaquin M.
    Bettcher, Brianne M.
    Granholm, Ann-Charlotte
    FREE RADICAL BIOLOGY AND MEDICINE, 2018, 114 : 110 - 121
  • [10] Complement dysregulation and Alzheimer's disease in Down syndrome
    Veteleanu, Aurora
    Pape, Sarah
    Davies, Kate
    Kodosaki, Eleftheria
    Hye, Abdul
    Zelek, Wioleta M.
    Strydom, Andre
    Morgan, B. Paul
    ALZHEIMERS & DEMENTIA, 2023, 19 (04) : 1383 - 1392